Elevated Systemic Immunity-Inflammation Index As A Predictor Of Five-Year Survival In Patients With Lung Cancer: A Retrospective Cohort Study

Agreda M.M.M.V.; Cabrejo A.B.; Caballero-Alvarado J.; Zavaleta-Corvera C.; Muente-Alva L.S. · Surgical Chronicles (2023)

Resumen

Objective: Evaluate if the elevated systemic immune inflammation index (SIII) is a predictor of five-year survival in patients with lung cancer (LC) treated at the Alta Complejidad “Virgen de la Puerta” Hospital and Víctor Lazarte Echegaray Hospital during a period 2013 to 2018. Methods: A retrospective cohort analytical study was carried out in which 134 patients with lung cancer were included, divided into 2 groups according to whether or not they were exposed to elevated SIII (greater than 660), in which the five-year survival was determined by analysis of Kaplan-Meier and multivariate analysis by Cox regression to obtain the estimate of the Hazard Ratio. Results: Survival at 12, 36 and 60 months was analyzed, where patients with elevated SIII had a survival of 62.6%, 48.7% and 10.3%, showing a trend of lower survival at 5 years (HR: 7.762, CI95 %: 3,226-18,678). No patient with a history of smoking had survived 5 years after the PC was diagnosed; the multivariate analysis determined that smoking is a factor of worse survival (HR: 2,836, 95% CI: 1,213-6,630). Cancer stages III and IV were associated with a worse survival prognosis compared to stage I, meaning an increase in mortality of 9.91 and 14.5 times, respectively. Conclusion: the elevated systemic immune inflammation index (SIII) is a predictor of five-year survival in patients with LC.

Instituciones: Universidad Privada Antenor Orrego